SERO Serologicals (MM)

Serologicals Corporation (NASDAQ: SERO) today announced that Upstate Group, its wholly owned subsidiary, has released a new, more cost efficient Western blotting detection kit based on its high quality Visualizer(TM) Western Blot Detection Kit. Upstate's new Visualizer(TM) EC offers the highest signal-to-noise ratios of any existing luminal peroxidase formulations on the market, providing high sensitivity and low backgrounds at a more economical price. Based on Upstate's original Visualizer(TM) product, the Visualizer(TM) EC is designed with a high glow reaction chemiluminescent substrate that is both sensitive and long lasting. The product is available as 20 or 50 mini-blot kits, as well as a 5 mini-blot sample kit. "Higher reliability at a lower cost is an option our customers want," said David A. Dodd, President and Chief Executive Officer of Serologicals. "Upstate has a full pipeline of new products like Visualizer(TM) EC that will help speed research, drug discovery and bioprocessing." Upstate is a leading research discovery provider of the highest quality cell signaling products and services to the life science market. Its customers are biomedical researchers at drug discovery companies and academic institutions in the key disciplines of oncology, immunology, proteomics, cardiology and neurology. Known for its enabling, innovative solutions to help understand the biology of kinases, chromatin, G-proteins and cytokines, Upstate's advanced cell biology tools - drug screening services, enzymes, state specific antibodies, siRNA kits, multiplex assays are used by thousands of customers worldwide, every day to accelerate improving human health. Upstate, a Serologicals company, is headquartered in Charlottesville, VA, with locations in Lake Placid, NY, and Dundee, Scotland. For more information, please visit our website www.upstate.com. Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA., is a global leader in developing and commercializing consumable biological products, enabling technologies and services in support of biological research, drug discovery, and the bioprocessing of life-enhancing products. Our customers include researchers at major life science companies and leading research institutions involved in key disciplines, such as neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and stem cell research. In addition, Serologicals is the world's leading provider of monoclonal antibodies for the blood typing industry. Serologicals employs a total of more than 1,000 people worldwide in three Serologicals' companies: Chemicon International, headquartered in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville, VA. and Celliance Corporation, headquartered in Atlanta, GA. For more information, please visit our website: www.serologicals.com This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words or phrases such as "should result," "are expected to," "we anticipate," "we estimate," "we project" and similar expressions are intended to identify forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. These risks and uncertainties include, without limitation, our ability to continue to introduce new products at a rapid pace and the acceptance of such products by our customers. Serologicals is a registered trademark of Serologicals Investment Company. Visualizer is a registered trademark of Upstate USA, Inc.